Doses of Oral hPTH(1-34) May Safely be Adjusted to Suit Needs of Patients with Hypoparathyroidism, Phase 2 Study Shows
The pharmacological properties of hPTH(1-34) allow the oral medication to be administered at different dosing regimens to suit the individual needs of patients with hypoparathyroidism, according to data from a Phase 2 study. The findings were presented in the poster “An Evaluation of the Pharmacodynamic Effects of…